LINC00589 and neoplasm: In glioma 20, liver cancer 19, lung cancer 27, breast cancer 21, melanoma 25, and gastric cancer 23, TSLNC8 consistently acts as a tumor suppressor, effectively inhibiting tumor progression and reducing chemoresistance when overexpressed.